Shijiazhuang Pharmaceutical Innovation (300765.SZ) subsidiary SYS6090 has initiated Phase Ib/II clinical trials.

Zhizhong Finance APP News, China Shiyao Innovation (300765.SZ) announced that its holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability, and efficacy of SYS6090 injection in participants with advanced or metastatic colorectal cancer.